Lupin Limited, a leading pharmaceutical company based in India, received World Health Organization (WHO) prequalification for its 200mg pretomanid tablet. This achievement adds another manufacturer to the market for a critical component of WHO-endorsed six-month drug-resistant TB treatments. Having multiple producers strengthens the global supply of pretomanid, ensures consistent quality, and drives competition that helps further lower costs.

PeerLINC’s G-TEC brought together experts from 18 countries to review complex DR-TB cases from the Philippines and India, demonstrating how collective expertise can guide safer and more effective treatment decisions.

As part of India’s accelerated rollout of the WHO-recommended six-month, all-oral BPaLM/BPaL regimen for drug-resistant tuberculosis (DR-TB), a total of 136 TB physicians from both public and private sectors gathered for high-level experience-sharing workshops in New Delhi and Mumbai.